Symantec Corporation (NASDAQ:SYMC) sacked its President and Chief Executive Officer Steve Bennett as slowdown in PC sales saw Symantec’s revenue decline. The company has also been struggling to hack into the mobile devices market. Symantec Corporation (NASDAQ:SYMC) shares after opening at $18.71 moved to $18.73 on last trade day and at the end of the day closed at $18.20. Company price to sales ratio in past twelve months was calculated as 1.86 and price to cash ratio as 3.26. Symantec Corporation (NASDAQ:SYMC) showed a negative weekly performance of -9.72%.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares fell -7.99% in last trading session and ended the day on $159.79. ALXN return on equity ratio is recorded as 11.20% and its return on assets is 8.50%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) yearly performance is 73.05%.
Illumina (NASDAQ:ILMN) Director Gerald Moeller sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $161.92, for a total value of $1,619,200.00. Following the completion of the sale, the director now directly owns 14,620 shares of the company’s stock, valued at approximately $2,367,270. Illumina, Inc. (NASDAQ:ILMN) shares moved down -5.42% in last trading session and was closed at $152.60, while trading in range of $152.60 – $162.35. Illumina, Inc. (NASDAQ:ILMN) year to date (YTD) performance is 37.99%.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global leader in providing therapies for rare genetic diseases, announced the appointment of Dennis J. Slamon, M.D. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) weekly performance is -4.42%. On last trading day company shares ended up $73.93. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) distance from 50-day simple moving average (SMA50) is -0.86%. Analysts mean target price for the company is $84.79.